Aston Sci. Inc., a clinical stage biopharmaceutical company specializing in clinical development of therapeutic cancer vaccines,…
Category:
Biotechnology
-
-
Biotechnology
Bactolife receives USD 5 million in new funding to address gastrointestinal infections worldwide
by PRNewswireby PRNewswireBactolife today announced that the Bill & Melinda Gates Foundation has committed, in alignment with…
-
Biotechnology
BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington’s Disease
by PRNewswireby PRNewswireAsklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, has received…
-
Biotechnology
Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75
by PRNewswireby PRNewswireRoche (SIX: RO, ROG;OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 test…
-
Biotechnology
UPL AND ORO AGRI ANNOUNCE DEVELOPMENT AND DISTRIBUTION AGREEMENT FOR ORANGE OIL MULTIFUNCTIONAL BIOPROTECTION PRODUCT
by PRNewswireby PRNewswireUPL Ltd. (NSE: UPL & BSE: 512070 LSE: UPLL) (‘UPL’) a global provider of…
-
Biotechnology
Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral
by PRNewswireby PRNewswirePneumagen, a clinical stage biotech company developing Neumifil, an intranasal, broad-spectrum antiviral treatment to…
-
Biotechnology
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
by PRNewswireby PRNewswireChemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and…
-
Biotechnology
European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International
by PRNewswireby PRNewswireHansa Biopharma AB, ‘Hansa’ (Nasdaq: HNSA) (Stockholm: HNSA), pioneer in enzyme technology for rare immunological…
-
Biotechnology
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004
by PRNewswireby PRNewswireInmagene Biopharmaceutical (“Inmagene”) and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the…
-
Biotechnology
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
by PRNewswireby PRNewswireHalozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Roche’s Phase III IMscin001 study evaluating…
